NumFin

Sarepta Therapeutics, Inc.

Symbol: SRPT

NASDAQ

130.63

USD

Market price today

  • 726.6405

    P/E Ratio

  • -300.6475

    PEG Ratio

  • 12.35B

    MRK Cap

  • 0.00%

    DIV Yield

Sarepta Therapeutics, Inc. (SRPT) Financial Statements

Download
AnnualQuarterly
LinearLog
On the chart you can see the default numbers in dynamics for Sarepta Therapeutics, Inc. (SRPT). Companys revenue shows the average of 153.75 M which is 5.127 % gowth. The average gross profit for the whole period is 119.498 M which is 5.178 %. The average gross profit ratio is -3.321 %. The net income growth for the company last year performance is -0.238 % which equals -2.304 % % on average for the whole company history.,

AnnualQuarterly
10Y20Y30Y40Y

Balance Sheet

Diving into the fiscal trajectory of Sarepta Therapeutics, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.044. In the realm of current assets, SRPT clocks in at 2579.331 in the reporting currency. A significant portion of these assets, precisely 1676.25, is held in cash and short-term investments. This segment shows a change of -0.157% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 22.106, if any, in the reporting currency. This indicates a difference of -29.421% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 1132.515 in the reporting currency. This figure signifies a year_over_year change of -0.136%. Shareholder value, as depicted by the total shareholder equity, is valued at 859.337 in the reporting currency. The year over year change in this aspect is 1.232%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 439.706, with an inventory valuation of 322.86, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 29.62. Account payables and short-term debt are 164.92 and 123.33, respectively. The total debt is 1396.81, with a net debt of 968.38. Other current liabilities amount to 315, adding to the total liabilities of 2405.24. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

balance-sheet.row.cash-and-short-term-investments

6661.251676.31989.42115.9
1938.6
1124.7
1173.9
1079.1
317.8
192.5
210.3
257
187.7
39.9
33.6
48.4
11.5
25.1
33.2
47.1
19.5
37.6
19.3
25.6
32.1
11.6
8.5
17.6
3
0.9

balance-sheet.row.short-term-investments

4411.671247.81022.60
435.9
289.7
803.1
479.4
195.4
112.2
136.8
0
0
0
0
0.2
0.3
0.3
13
12.5
2.9
25.1
8.9
14.5
6.2
2.9
0
0
0
0.2

balance-sheet.row.net-receivables

1480.51439.7259.7171.6
138.6
93.9
49
29.5
5.2
4
2.4
3.5
4.7
3.6
3.2
2.1
5
2.9
0.1
1.2
0
0
0.5
1.7
0
0
0
0
0
0

balance-sheet.row.inventory

1167.28322.9204186.2
232
171.4
125.4
83.6
12.8
26.9
33.5
7.3
0
-3.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

446.86140.57.76.1
4.1
5.2
77.8
36.5
0.9
1.2
1.6
3.1
1.5
5.3
1
0.8
0.6
0.8
0.7
0.4
0.7
0.8
0.6
0.2
1
0.1
0.5
0.1
0
0

balance-sheet.row.total-current-assets

9967.662579.32557.92604.1
2485.2
1468.9
1426.2
1228.6
373.5
224.5
247.8
270.8
193.9
45.2
37.8
51.3
17
28.7
33.9
48.7
20.2
38.4
20.4
27.5
33.1
11.7
9
17.7
3
0.9

balance-sheet.row.property-plant-equipment-net

1402.1357.1245236.7
282.2
167.6
97
43.2
37.8
37.3
38.5
15
3.4
4.3
4
2.5
5.2
6.8
4.3
5.6
6.3
7
6.6
4.9
1
0.4
0.4
0.4
0.5
0.9

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

67.1429.67.614.2
13.6
12.5
11.6
14.4
8.1
6.6
5.9
5
4.9
4.8
4
3.8
3.3
3.1
2.6
2.1
2
1.7
1.6
1.4
0.9
0.8
0.7
0.6
0
0.4

balance-sheet.row.goodwill-and-intangible-assets

67.1429.67.614.2
13.6
12.5
11.6
14.4
8.1
6.6
5.9
5
4.9
4.8
4
3.8
3.3
3.1
2.6
2.1
2
1.7
1.6
1.4
0.9
0.8
0.7
0.6
0
0.4

balance-sheet.row.long-term-investments

66.5522.131.334.9
38.8
31.9
107.3
10
0.8
0.8
0
0.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

166.7400114.8
151.9
130.1
-107.3
-10
-0.8
-0.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

1054.37276.4286.6143.3
13
11.8
107.3
21.8
4
4.5
2.8
0
2.8
0.2
0.1
2.5
0
0
0
0
0
0
0
0
0
0
0.1
0.1
0.7
0.1

balance-sheet.row.total-non-current-assets

2756.9685.2570.5543.9
499.5
353.9
215.9
79.3
50.6
49.2
47.2
20.8
11.1
9.2
8.1
8.7
8.5
9.9
6.9
7.8
8.3
8.8
8.2
6.3
2
1.2
1.2
1.1
1.2
1.4

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

12724.563264.63128.43148
2984.7
1822.8
1642.1
1308
424.1
273.8
295
291.6
205
54.4
46
60
25.5
38.6
40.9
56.4
28.5
47.1
28.6
33.8
35.1
12.9
10.2
18.8
4.2
2.3

balance-sheet.row.account-payables

454.2164.995.976.7
111.1
68.1
33.8
8.5
29.7
20.2
12.4
17.6
7.5
9.4
1.3
1.4
2
3
1.4
1.9
1.5
3.1
4.5
2.8
1.3
0.7
0.9
0.2
0.2
0.1

balance-sheet.row.short-term-debt

878.14123.315.5271.7
193.6
7.8
134.1
6.2
10.1
8.4
2.6
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-payables

77.5513.812.50.2
0
0
0.3
0.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

5002.371132.51601.91138.4
1072.9
729.6
420.6
424.9
6
15
3.7
1.6
1.7
1.8
1.8
1.9
2
2.1
0
0
0
0
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

1732437485574.2
663.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

281.07---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

649.5331541915.1
22.1
196.7
2.5
70.4
32.3
30.3
18.6
14.9
68
7.8
41.2
28.6
3
5.9
1.7
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.3
0.3
0.1
0.2

balance-sheet.row.total-non-current-liabilities

7186.51751.62123.81767.2
1806.9
739.9
436.1
430.4
12
21.1
10.5
8.4
2.4
2.8
2.9
2.9
2.5
2.5
0
0
0
0
0
0
0
0
0
0
3.1
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

561.2614173.141.5
80.4
47.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

9398.262405.22743.42220
2223
1004.6
609.8
518.7
87.4
83.4
47.4
44.4
81.3
23.4
48.8
36.4
9.8
12.3
3.2
2.7
2.2
3.8
5.1
3.3
1.7
1
1.2
0.5
3.4
0.3

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
0
0
0
0
0

balance-sheet.row.common-stock

0.04000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3.1

balance-sheet.row.retained-earnings

-17799.11-4446.2-3910.2-3206.7
-2848.1
-2294
-1578.9
-1217
-1166.3
-899.1
-679
-543.2
-431.3
-310
-307.6
-275.5
-250.3
-226.4
-203.7
-172.6
-156
-131.2
-116.6
-87.2
-60.3
-51.1
-42.8
-16
-12.4
-10.3

balance-sheet.row.accumulated-other-comprehensive-income-loss

-1.470.9-1.70
0
0.1
-0.1
-0.4
-0.1
-0.1
-0.1
-17.3
-16.7
-15.8
-15
-14
-12.9
-11.8
0
0
-0.1
-0.3
0.7
1
-11.7
-2.5
-2.4
-2.3
-1.9
0.1

balance-sheet.row.other-total-stockholders-equity

21126.835304.64296.84134.8
3609.9
3112.1
2611.3
2006.6
1503.1
1089.5
926.8
807.8
571.6
356.7
319.8
313.1
279
264.5
241.4
226.3
182.4
174.9
139.3
116.7
96.3
65.5
54.2
36.6
15.1
9.2

balance-sheet.row.total-stockholders-equity

3326.3859.3384.9928
761.8
818.2
1032.3
789.2
336.7
190.3
247.7
247.2
123.7
31
-2.8
23.6
15.7
26.4
37.7
53.7
26.3
43.4
23.5
30.5
33.4
11.9
9
18.3
0.8
2.1

balance-sheet.row.total-liabilities-and-stockholders-equity

12724.563264.63128.43148
2984.7
1822.8
1642.1
1308
424.1
273.8
295
291.6
205
54.4
46
60
25.5
38.6
40.9
56.4
28.5
47.1
28.6
33.8
35.1
12.9
10.2
18.8
4.2
2.4

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

3326.3859.3384.9928
761.8
818.2
1032.3
789.2
336.7
190.3
247.7
247.2
123.7
31
-2.8
23.6
15.7
26.4
37.7
53.7
26.3
43.4
23.5
30.5
33.4
11.9
9
18.3
0.8
2.1

balance-sheet.row.total-liabilities-and-total-equity

12724.56---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

4433.771269.91053.934.9
474.7
321.6
803.1
489.3
195.4
112.2
136.8
0.6
0
0
0
0.2
0.3
0.3
13
12.5
2.9
25.1
8.9
14.5
6.2
2.9
0
0
0
0.2

balance-sheet.row.total-debt

5512.351396.81617.41138.4
1072.9
729.6
420.6
431.1
16.1
23.4
6.3
1.7
1.8
1.8
1.9
2
2.1
2.1
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-debt

3262.77968.4650.6-977.5
-429.8
-105.5
49.7
-168.6
-106.3
-56.9
-67.2
-255.3
-185.9
-38.1
-31.7
-46.3
-9.1
-22.7
-20.2
-34.6
-16.7
-12.5
-10.4
-11.1
-25.9
-8.7
-8.5
-17.6
-3
-0.7

Cash Flow Statement

The financial landscape of Sarepta Therapeutics, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -0.652. The company recently extended its share capital by issuing 51.25, marking a difference of 0.000 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -165803000.000 in the reporting currency. This is a shift of -0.842 from the previous year. In the same period, the company recorded 58.89, 102, and -73.76, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 147.52, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

cash-flows.row.net-income

16.9-536-703.5-418.8
-554.1
-715.1
-361.9
-50.7
-267.3
-220
-135.8
-112
-121.3
-2.3
-32.2
-25.2
-24
-27.2
-31.1
-16.7
-24.8
-14.6
-29.4
-26.9
-9.2
-8.3
-26.7
-3.6
-2.1
-2.6

cash-flows.row.depreciation-and-amortization

49.6558.941.938
26.9
30.5
12.2
8.1
5.6
5.2
3.7
1.3
1.5
1.3
1.5
1.4
1.5
2
2.1
2
1.9
1.5
1.3
0.6
0.4
0.3
0.2
0.5
0.5
0.5

cash-flows.row.deferred-income-tax

0383.5015.8
10.6
-8.4
-1.4
-0.1
0.4
0.8
5.3
11.5
0
0.3
1.2
0.5
0.4
-0.3
-0.3
-0.4
-0.4
-0.5
-0.5
-0.1
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

141.26182.5233113.9
108.1
78.6
50.1
30.5
30
32.1
20.3
11.1
3.1
3.1
3.2
2.4
0.2
0.3
0.5
0.4
0.4
0.5
0.5
0.1
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-681.64-481.1-39.5-98.2
554.1
-66.9
-107.9
-97.5
-15.8
32
-22.1
12.3
-5.3
6.9
-0.3
2.9
-2.8
-0.4
1.4
-0.4
-1.4
-1.1
2.6
0.8
-0.3
0.4
0.2
0.1
0.1
0.1

cash-flows.row.account-receivables

-154.97-185.7-61.6-51.6
-10.5
-41.8
-19.6
-24.2
-1.3
-1.6
1.1
2.8
-3.6
-1.1
0
2.6
-1.8
-2.8
0.8
-0.9
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-207.92-147.7-50.8-83.8
-60.6
-45.9
-41.8
-70.8
-12.8
-147
-244.9
-234.8
-115
-24.6
0
-17.8
-9.8
-19
0
-45.9
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

-40.43-50.1147.623.3
42
123
90.2
12.9
7.3
18.3
10.8
9.5
-1.7
8
0
0.3
-1
2.5
0.6
0.5
-1.5
1.8
1.8
1.7
0
0
0
0
0
0

cash-flows.row.other-working-capital

-278.32-97.5-74.614
583.1
-102.1
-136.6
-15.4
-9
162.2
210.9
234.8
115
24.6
-0.3
17.8
9.8
19
0
45.9
0.1
-2.9
0.8
-0.9
-0.3
0.4
0.2
0.1
0.1
0.1

cash-flows.row.other-non-cash-items

375.58-108.9142.7-94
-38.1
224.8
20.2
-122.3
1.3
0.4
0
11.1
92.3
-33
11.5
9.2
12.4
0.8
6.8
0.4
0.5
-3.3
5.1
12.8
0
0
19.6
0
-0.1
0.3

cash-flows.row.net-cash-provided-by-operating-activities

-533.67000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-110.3-87.3-30.8-38.5
-82.2
-62.7
-64.3
-21.2
-6.9
-4.8
-26.8
-3.8
-1.1
-2.3
-2
-2
-1.2
-2.1
-1.5
-1.5
-1.1
-1.6
-2.8
-4.2
-0.8
-0.2
-2.3
-0.3
-0.1
-0.3

cash-flows.row.acquisitions-net

0000
0
-172.6
3.2
-9.2
1.5
1.4
1.4
0
0
0
0
0
0
0.9
0.7
0.4
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-1838.63-2048.9-1936.9-30
-1333.6
-1193.6
-1172
-589.5
-195.4
-172.7
-274.4
-7.9
0
0
0
0
0
-0.1
-15
-13.1
-13.1
-44.4
-19.1
-8.1
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

1897.341868.5923.2466
1189.5
1715.6
865.8
306.9
112.1
185.9
142.2
0
0
0
0
0.1
0.9
12.8
14.4
3.7
35.5
31
19.9
0
0
0
0
0
0.2
0

cash-flows.row.other-investing-activites

353.33102-2.497.9
104.6
0
-3.2
134.2
-1.5
-1.4
-1.4
0
0
0
0
0
-0.9
-0.9
-0.7
-0.4
-0.5
-0.4
-0.5
-0.5
-0.3
-0.3
-0.3
-0.2
0
0

cash-flows.row.net-cash-used-for-investing-activites

40.5-165.8-1046.9495.4
-121.7
286.7
-370.5
-178.8
-90.2
8.4
-159
-11.7
-1.1
-2.3
-2
-1.9
-1.2
10.6
-2
-10.9
20.8
-15.5
-2.4
-12.8
-1.1
-0.5
-2.6
-0.5
0.1
-0.3

cash-flows.row.debt-repayment

-157.87-73.8-823.20
-291.1
-244.9
-267.2
-54.8
-7.6
-2.6
-0.1
-0.1
-0.1
-0.1
-0.1
-0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

73.3951.230548.5
312.1
365.4
513.4
354
364.8
130.8
104.2
146
178.7
32.4
2.6
47.8
0.1
18.7
8.2
43.5
7.1
35.1
22
10.8
27.4
8.2
0.2
18.4
4
0

cash-flows.row.common-stock-repurchased

000-7.8
-4.8
-4.3
0
0
0
0
0
0
0
0
0
0
0.2
0.8
0
0
0
0.1
0.1
0.1
0
0
0
-0.3
0
0.9

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

173.24147.51025.720.8
666.2
526.5
284
588.9
20.9
19.6
0
-0.2
0
0
0
0
-0.3
-0.8
0
0
0
-0.1
-0.1
-0.1
0
0
0
0.1
-0.1
0

cash-flows.row.net-cash-used-provided-by-financing-activities

45.35125232.5561.6
682.3
642.6
530.1
888.1
378.1
147.8
104.2
145.7
178.6
32.3
2.5
47.8
0
18.7
8.2
43.5
7.1
35.1
22
10.8
27.4
8.2
0.2
18.2
3.9
0.9

cash-flows.row.effect-of-forex-changes-on-cash

3.573.400
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
9.3
3.5
1.5
0

cash-flows.row.net-change-in-cash

-444.25-538.3-1139.7613.8
668.1
472.8
-229
477.3
42.1
6.8
-183.4
69.3
147.8
6.3
-14.7
37.1
-13.6
4.6
-14.4
17.9
4.1
2.1
-0.7
-14.8
17.2
0.2
0.2
18.2
3.9
-1.2

cash-flows.row.cash-at-end-of-period

2287.75428.4985.82125.5
1511.7
843.6
370.8
599.8
122.4
80.3
73.6
257
187.7
39.9
33.6
48.3
11.2
24.8
20.2
34.6
16.7
12.5
10.4
11.1
25.9
8.7
17.8
21.2
4.6
-1.2

cash-flows.row.cash-at-beginning-of-period

2732.01966.82125.51511.7
843.6
370.8
599.8
122.6
80.3
73.6
257
187.7
39.9
33.6
48.3
11.2
24.8
20.2
34.6
16.7
12.5
10.4
11.1
25.9
8.7
8.5
17.6
3
0.7
0

cash-flows.row.operating-cash-flow

-533.67-501-325.3-443.2
107.5
-456.5
-388.7
-232
-245.8
-149.5
-128.5
-64.7
-29.7
-23.7
-15.2
-8.8
-12.3
-24.7
-20.6
-14.7
-23.8
-17.5
-20.3
-12.8
-9.1
-7.6
-6.7
-3
-1.6
-1.8

cash-flows.row.capital-expenditure

-110.3-87.3-30.8-38.5
-82.2
-62.7
-64.3
-21.2
-6.9
-4.8
-26.8
-3.8
-1.1
-2.3
-2
-2
-1.2
-2.1
-1.5
-1.5
-1.1
-1.6
-2.8
-4.2
-0.8
-0.2
-2.3
-0.3
-0.1
-0.3

cash-flows.row.free-cash-flow

-643.98-588.3-356.2-481.7
25.3
-519.2
-453
-253.2
-252.7
-154.3
-155.4
-68.5
-30.8
-26
-17.2
-10.8
-13.6
-26.8
-22.1
-16.1
-24.9
-19.1
-23
-17
-9.9
-7.8
-9
-3.3
-1.7
-2

Income Statement Row

Sarepta Therapeutics, Inc.'s revenue saw a change of 0.333% compared with the previous period. The gross profit of SRPT is reported to be 1092.99. The company's operating expenses are 1360.82, showing a change of 2.377% from the last year. The expenses for depreciation and amortization are 58.89, which is a -0.060% change from the last accounting period. Operating expenses are reported to be 1360.82, which shows a 2.377% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.501% year-over-year growth. The operating income is -267.82, which shows a -0.501% change when compared to the previous year. The change in the net income is -0.238%. The net income for the last year was -535.98.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

income-statement-row.row.total-revenue

1403.31243.3933701.9
540.1
380.8
301
154.6
5.4
1.3
9.8
14.2
37.3
47
29.4
17.6
21.3
11
0.1
4.8
0.4
1
0.8
0.7
1.3
0.1
0.2
0.1
0.1
0.1

income-statement-row.row.cost-of-revenue

165.88150.314097
63.4
56.6
34.2
7.4
0.1
146.2
94.1
90.3
51.9
35.9
27.5
0
0
0
0
0
0
0
0
0
-0.4
0
-0.2
-0.5
-0.5
0

income-statement-row.row.gross-profit

1237.411093793604.8
476.7
324.2
266.8
147.2
5.3
-144.9
-84.3
-76.1
-14.6
11.1
2
17.6
21.3
11
0.1
4.8
0.4
1
0.8
0.7
1.7
0.1
0.4
0.6
0.6
0.1

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

826.06---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

589.63---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

-218.47---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

194.841.60.70.7
0.7
0.8
-0.7
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.4
0
0.2
0.5
0.5
0

income-statement-row.row.operating-expenses

1325.71360.81329.21054.5
1040.9
846.6
610.5
290.4
272
221.4
143.5
104.5
67
82.9
50.4
33.1
38.8
44.1
33.1
22.3
25.5
19.8
26.2
16.1
12
8.4
8.1
4.5
2.8
2.7

income-statement-row.row.cost-and-expenses

1498.131511.21469.21151.6
1104.3
903.2
644.7
297.8
272.2
221.4
143.5
104.5
67
82.9
50.4
33.1
38.8
44.1
33.1
22.3
25.5
19.8
26.2
16.1
11.5
8.4
7.9
4
2.3
2.7

income-statement-row.row.interest-income

-19.328616.50.4
3
7.2
6.8
1.8
0
0
0
0
0
0.7
0
0
0
0
1.9
0.8
0
0.5
0
0
1
0
0
0
0
0

income-statement-row.row.interest-expense

-6.322253.263.5
59.9
30.7
33.7
5.8
-0.5
0
0
0.3
0
0.1
0.3
0.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

-218.47---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

143.01-252.3-153.830.8
11.1
-191.6
10.1
96.6
-2.5
0.2
-2.8
-22
-91.9
33
-11.5
-9.2
-6.8
5
1.9
0.8
0.3
3.8
-4.5
-12.5
1
-0.1
-19
0.4
0.2
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

194.841.60.70.7
0.7
0.8
-0.7
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.4
0
0.2
0.5
0.5
0

income-statement-row.row.total-operating-expenses

143.01-252.3-153.830.8
11.1
-191.6
10.1
96.6
-2.5
0.2
-2.8
-22
-91.9
33
-11.5
-9.2
-6.8
5
1.9
0.8
0.3
3.8
-4.5
-12.5
1
-0.1
-19
0.4
0.2
0

income-statement-row.row.interest-expense

-6.322253.263.5
59.9
30.7
33.7
5.8
-0.5
0
0
0.3
0
0.1
0.3
0.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

-17.6458.962.737.6
34.9
52.9
0.9
1.1
5.6
5.2
3.7
1.3
1.5
1.3
1.5
1.4
1.5
2
2.1
2
1.9
1.5
1.3
0.6
0.4
0.3
0.2
0.5
0.5
0.5

income-statement-row.row.ebitda-caps

-73.7---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-94.83-267.8-536.2-449.7
-564.2
-522.3
-343.6
-171.6
-266.7
-220.2
-133.8
-90.3
-29.7
-35.9
-20.9
-15.5
-27.5
-33.1
-33
-17.5
-25
-18.9
-25.3
-15.4
-10.2
-8.3
-7.7
-3.9
-2.2
-2.6

income-statement-row.row.income-before-tax

34.06-520.1-690-418.9
-553.1
-713.9
-362.6
-48.6
-267.3
-220
-135.8
-112
-121.3
-2.3
-24
-24.7
-24
-28.2
-31.1
-16.7
-24.8
-14.6
-29.4
-8.3
-9.2
-8.4
-26.7
-3.5
-2
-2.6

income-statement-row.row.income-tax-expense

17.1615.913.5-0.2
1.1
1.2
-0.7
2.1
-7.6
-5.2
-1.7
20.4
91.6
-34.9
11.2
9.7
6.4
-5.9
0
0
0
-4.3
4
11.5
0
0
19
-0.3
-0.1
0

income-statement-row.row.net-income

16.9-536-703.5-418.8
-554.1
-715.1
-361.9
-50.7
-267.3
-220
-135.8
-112
-121.3
-2.3
-32.2
-25.2
-24
-27.2
-31.1
-16.7
-24.8
-14.6
-29.4
-26.9
-9.2
-8.3
-26.7
-3.6
-2.1
-2.6
Similar Stocks
You may also be interested in:
SRNE
Sorrento Therapeutics, Inc..
0.014 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
8.8 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.03 USD
NASDAQ
GUBRA.CO
Gubra A/S.
296 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.04 NOK
OSL
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.05 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

Frequently Asked Question

What is Sarepta Therapeutics, Inc. (SRPT) total assets?

Sarepta Therapeutics, Inc. (SRPT) total assets is 3264576000.000.

What is enterprise annual revenue?

The annual revenue is 810245000.000.

What is firm profit margin?

Firm profit margin is 0.882.

What is company free cash flow?

The free cash flow is -6.851.

What is enterprise net profit margin?

The net profit margin is 0.012.

What is firm total revenue?

The total revenue is -0.068.

What is Sarepta Therapeutics, Inc. (SRPT) net profit (net income)?

The net profit (net income) is -535977000.000.

What is firm total debt?

The total debt is 1396808000.000.

What is operating expences number?

The operating expences are 1360817000.000.

What is company cash figure?

Enretprise cash is 427290000.000.